(2026). Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC). The Oncologist.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Niraparib in Pancreatic Cancer with Germline or Somatic DNA Damage Repair (DDR) Gene Alterations (BRCA and Beyond): A Phase II Study (NIRA-PANC)."
The Oncologist 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Niraparib in Pancreatic Cancer with Germline or Somatic DNA Damage Repair (DDR) Gene Alterations (BRCA and Beyond): A Phase II Study (NIRA-PANC)."
The Oncologist, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.